Loratadine for use as an antiarrhythmic
CA 2276324 C · Owner: Pfizer Products Inc. · Inventors: Friedrich, Tilman; Satler, Carol Ann; Buckland, Guy
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a pharmaceutical composition for treating arrhythmias including atrial fibrillation in mammals using loratadine, i. e. ethyl 4-(8-chloro-5,6-dihydro-11Hbenzo5,6cyclohepta1,2-bpyridin-11-ylidene)-1-piperidine-carboxylate of the formula I, or a metabolite thereof e. g. descarboethoxycarbonyl, loratadine.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 28, 1999 and granted August 19, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 28, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 28, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.